使用智能手机与机器学习量化帕金森病严重程度:移动帕金森病评分
这项观察性研究利用智能手机应用完成5项任务,通过机器学习方法生成0至100分的移动帕金森病评分(mPDS),分数越高表示越严重。mPDS能捕捉日内症状波动(平均变化13.9分),与MDS-UPDRS总分(r=0.81)及第三部分(r=0.88)等标准评估相关,并对多巴胺能治疗有反应(平均改善16.3分)。
要点
- mPDS基于6148次智能手机活动评估生成,步态特征贡献最大(33.4%)。
- mPDS与MDS-UPDRS总分(r=0.81)及第三部分(r=0.88)等标准评估相关良好。
- mPDS可检测日内症状波动,并对多巴胺能治疗有反应(平均改善16.3分)。
核心结论
- 研究创建并验证了基于智能手机评估的客观帕金森病严重程度评分mPDS的构念效度。
- 该评分可补充标准帕金森病评估,提供频繁、客观的真实世界评估,可能有助于临床照护和新疗法评估。
研究设计与样本
- 观察性研究,纳入帕金森病患者通过智能手机应用远程完成语音、手指敲击、步态、平衡和反应时间5项任务。
- 采用基于机器学习的新方法生成移动帕金森病评分(mPDS),评分范围0至100分,分数越高表示越严重。
- mPDS源自129名个体的6148次智能手机活动评估(平均[SD]年龄58.7[8.6]岁;56名[43.4%]女性)。
- 23名帕金森病患者(平均[SD]年龄64.6[11.5]岁;11名[48%]女性)和17名无帕金森病个体(平均[SD]年龄54.2[16.5]岁;12名[71%]女性)完成了临床现场评估。
主要发现
- 步态特征对总mPDS贡献最大(33.4%)。
- mPDS检测到症状波动,日内平均(SD)变化为13.9(10.3)分(0至100分量表)。
- mPDS与MDS-UPDRS总分相关良好(r=0.81;P<.001),与MDS-UPDRS第三部分相关良好(r=0.88;P<.001)。
- mPDS与计时起立行走评估相关良好(r=0.72;P=.002),与Hoehn和Yahr分期相关良好(r=0.91;P<.001)。
- mPDS对多巴胺能治疗有反应,平均(SD)改善16.3(5.6)分。
关键数值与推荐
- mPDS评分范围为0至100分,分数越高表示帕金森病严重程度越高。
- mPDS与MDS-UPDRS总分相关系数r=0.81(P<.001),与MDS-UPDRS第三部分相关系数r=0.88(P<.001)。
- mPDS与计时起立行走评估相关系数r=0.72(P=.002),与Hoehn和Yahr分期相关系数r=0.91(P<.001)。
- mPDS检测到日内症状波动平均(SD)变化13.9(10.3)分。
- mPDS对多巴胺能治疗的平均(SD)改善为16.3(5.6)分。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Current Parkinson disease (PD) measures are subjective, rater-dependent, and assessed in clinic. Smartphones can measure PD features, yet no smartphone-derived rating score exists to assess motor symptom severity in real-world settings. OBJECTIVES: To develop an objective measure of PD severity and test construct validity by evaluating the ability of the measure to capture intraday symptom fluctuations, correlate with current standard PD outcome measures, and respond to dopaminergic therapy. DESIGN, SETTING, AND PARTICIPANTS: This observational study assessed individuals with PD who remotely completed 5 tasks (voice, finger tapping, gait, balance, and reaction time) on the smartphone application. We used a novel machine-learning-based approach to generate a mobile Parkinson disease score (mPDS) that objectively weighs features derived from each smartphone activity (eg, stride length from the gait activity) and is scaled from 0 to 100 (where higher scores indicate greater severity). Individuals with and without PD additionally completed standard in-person assessments of PD with smartphone assessments during a period of 6 months. MAIN OUTCOMES AND MEASURES: Ability of the mPDS to detect intraday symptom fluctuations, the correlation between the mPDS and standard measures, and the ability of the mPDS to respond to dopaminergic medication. RESULTS: The mPDS was derived from 6148 smartphone activity assessments from 129 individuals (mean [SD] age, 58.7 [8.6] years; 56 [43.4%] women). Gait features contributed most to the total mPDS (33.4%). In addition, 23 individuals with PD (mean [SD] age, 64.6 [11.5] years; 11 [48%] women) and 17 without PD (mean [SD] age 54.2 [16.5] years; 12 [71%] women) completed in-clinic assessments. The mPDS detected symptom fluctuations with a mean (SD) intraday change of 13.9 (10.3) points on a scale of 0 to 100. The measure correlated well with the Movement Disorder Society Unified Parkinson Disease's Rating Scale total (r = 0.81; P < .001) and part III only (r = 0.88; P < .001), the Timed Up and Go assessment (r = 0.72; P = .002), and the Hoehn and Yahr stage (r = 0.91; P < .001). The mPDS improved by a mean (SD) of 16.3 (5.6) points in response to dopaminergic therapy. CONCLUSIONS AND RELEVANCE: Using a novel machine-learning approach, we created and demonstrated construct validity of an objective PD severity score derived from smartphone assessments. This score complements standard PD measures by providing frequent, objective, real-world assessments that could enhance clinical care and evaluation of novel therapeutics.
引用
- Zhan A, Mohan S, Tarolli C, et al. Using Smartphones and Machine Learning to Quantify Parkinson Disease Severity: The Mobile Parkinson Disease Score. JAMA Neurol. 2018. PMID: 29582075. doi:10.1001/jamaneurol.2018.0809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。